The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs) Meeting Abstract
| Authors: | Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; Ramzan, H.; Futran, A.; Xu, C.; Greenwood, J.; Mondal, S.; Masse, C.; Levine, R. L.; Skoda, R. C.; Dunbar, A. |
| Abstract Title: | The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6722 |
| End Page: | 6723 |
| Language: | English |
| ACCESSION: | WOS:000893223206328 |
| DOI: | 10.1182/blood-2022-162621 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work